TECH — Bio-Techne Corporation

Market sentiment is deal-anchored: as of 2026-09-13, the $72.12 price sits about 1.2% below the $73.00 all-cash Merck KGaA offer, and analyst consensus is Hold with a $65.78 average target. The 33.6% three-month and 41.8% six-month rallies reflect the merger premium, not an independent improvement in standalone demand, and the thin spread means investors are mostly pricing deal-close probability rather than upside.

Revenue is stabilizing rather than accelerating. FY24 quarterly revenue grew from $276.9M in Sep-23 to $306.1M in Jun-24; FY25 was uneven at $289.5M, $297.0M, $316.2M, and $317.0M, including a Q4 FY25 GAAP operating loss of -$23.9M and EPS of -$0.11 from a one-off. FY26 revenue was slightly down overall at about $1.215B, but sequentially improved from $286.6M in Sep-25 to $321.2M in Jun-26, with Q4 FY26 revenue +1.3% YoY and organic +3%. Margins recovered sharply after the impaired Q4 FY25: operating margin was 16.6%, 18.4%, 24.2%, and 23.1% in the last four quarters, pushing TTM operating margin to 20.7% and TTM net income to about $181.9M. TTM FCF is healthy at about $263.2M and accruals are negative at -1.58%, meaning cash earnings exceed reported net income. Net: this is not a structural decline, but growth is low-single-digit and the inflection is modest.

Standalone valuation looks fair-to-rich. As of 2026-09-13, the $72.12 price gives TTM P/E 61.6 versus a 5-year average of 66.4, forward P/E of roughly 35.1 on next-FY EPS of $2.055, P/S of 9.3 versus a 5-year average of 9.81, P/B of 5.34, and EV/EBITDA of about 33.0. The TTM PEG of 0.399 looks misleading because forward EPS growth is only about 6.5% from $1.93 to $2.055; a more realistic forward PEG is above 5x. The stock is not cheap on standalone fundamentals, but the $73 cash offer caps near-term valuation around $72-$73.

Price is no longer trading off earnings. As of 2026-09-13, $72.12 effectively prices a roughly 95% probability of the $73 cash deal, leaving only about $0.88 upside to the offer. If the deal closes, earnings and estimates are largely irrelevant; if it breaks, the stock would likely reprice toward standalone value, which on roughly $2.05 forward EPS and a 25-30x multiple would be about $51-$62, and the analyst low target is $50. The playbook is deal-spread math, not earnings momentum: the market is not underpricing a turnaround, it is pricing near-certain close.

As of 2026-09-13, RSI was 55.94, price was -0.28% versus SMA20, +0.24% versus SMA50, and +17.72% versus SMA200, while the 52-week range was $43.20-$72.62. The stock is range-bound and pinned just under the $73 offer after a 33.6% three-month and 41.8% six-month run; it is neither overbought nor oversold. Entry timing offers little technical edge: upside to deal price is tiny, and a deal-break gap lower is the main technical risk.

• M&A arbitrage and deal mechanics dominate: the June 25, 2026 Merck KGaA agreement at $73.00 cash means TECH trades off merger-closing probability, regulatory clearances, and the September 23, 2026 shareholder vote rather than sector fundamentals.
• Life-sciences tools demand remains bifurcated: large pharma spending is resilient, while emerging biotech funding and VC-backed instrument capex remain cautious.
• Interest-rate path and biotech funding: lower rates would help early-stage biotech budgets and standalone growth, but this is largely irrelevant unless the Merck deal fails or is delayed.
• Sector consolidation: depressed life-science tools valuations and constrained biotech funding have encouraged strategic M&A, making TECH a target but also potentially reducing the standalone multiple.
• Regulatory and antitrust scrutiny of large healthcare and pharma transactions across major jurisdictions could delay or block closing.

• Special shareholder meeting on September 23, 2026 to vote on the Merck KGaA merger.
• Regulatory and antitrust clearances in major jurisdictions and expected deal closing on Merck KGaA's timeline.
• If the deal breaks or is delayed, standalone Q1 FY27 results and the organic growth trend become relevant again.
• Potential competing bid or revised offer, though this is low probability given the definitive agreement.

• Deal failure: shareholder vote or regulatory rejection could cause a sharp decline toward standalone value, and the current roughly $0.88 spread offers minimal compensation for that downside.
• Standalone growth remains weak: FY26 revenue was flat at about $1.22B and Q4 organic growth was only +3%, with emerging biotech funding still cautious.
• Standalone valuation is high: forward P/E of about 35x, P/S of 9.3x, and EV/EBITDA of 33x leave substantial multiple-compression risk if the merger fails.
• Merger arbitrage asymmetry: limited upside to $73 versus meaningful downside if the stock reprices to pre-deal levels around $54 or lower.
• Macro and R&D budget pressure plus biotech funding constraints could hurt standalone performance in a break scenario.

At $72.12 as of 2026-09-13, TECH is not a good standalone investment; it is a late-stage merger arbitrage with a tiny spread to the $73 cash offer and asymmetric downside if the deal breaks. Existing holders should weigh a potential roughly 1.2% gain against a possible 20%+ drawdown, and new money has poor risk/reward unless they are explicitly running a high-probability arbitrage strategy.

I used a probability-weighted merger-arbitrage valuation: about 95% probability of closing at the $73.00 cash offer plus about 5% probability of a standalone outcome near $55, based on roughly 27x next-FY EPS of $2.055 justified by low-single-digit organic growth, giving 0.95*73 + 0.05*55 = about $72.10; minor time discounting and pre-closing risk rounds to about $72.25. This is intentionally deal-driven, not a restatement of the analyst target or deterministic value score.